TORONTO, ON / ACCESSWIRE / December 12, 2019 / Soricimed Biopharma Inc. ("Soricimed" or the "Company"), a privately-held, science-based company today provided an update on its peptide-drug conjugate ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, ...

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...

̶ Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing ̶ ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)- ...

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG ("VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager ...

ORLANDO, Fla.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large ...

Oslo, Norway, 16 August 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces it has initiated a new research and development program ...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced an important milestone in its antibody-drug conjugate (ADC) program.

(MENAFN- GlobeNewsWire - Nasdaq) Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors ZURICH, SWITZERLAND, ...

SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors Preclinical efficacy and tolerability studies of SOT106 show promising results ...